The amount of clinical proof for the efficacy of Tomosynthesis in screening is significantly larger than the proof available in the early days of the transition from analog mammography to FFDM.
Results from studies in Europe using Tomosynthesis in population based screening and results from screening with Tomosynthesis in the USA are concordant around an increase in invasive cancer detection and a reduction in recall rates. As screening programs begin the adoption of Tomosynthesis, many questions arise around the practical implementation of the technology; however, current literature is primarily focused around the clinical results.
Presenters at the symposium will share their experiences with the challenges, the solutions and the early results from implementing Tomosynthesis in primary screening for breast cancer.
Friday, March 6th
14:00 - 15.30
Moderator of Session:
Prof. emer. Per Skaane
Sarah M. Friedewald, MD. Chicago, USA
The American experience
Dra. Marina Álvarez Benito / Dra. Sara Romero. Córdoba, España
The Spanish experience
Dott.ssa Daniela Bernardi. Trento, Italia
The Italian experience
Prof.emer. Per Skaane. Oslo, Norge
The Norwegian experience